SCM
NMRA icon

Stonepine Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Stonepine Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$190K – 98
2026
Q1 		$195K Buy
+100,000
New +$259K 0.08% 71

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stonepine Capital Management's NMRA Position: Q2 2026 in Review

Stonepine Capital Management sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 100,000 shares — an estimated $190K sold.

Stonepine Capital Management first reported a position in NMRA in Q1 2026 and held it in 1 quarter. The position peaked at $195K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Stonepine Capital Management reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 100,000 Neumora Therapeutics shares in Q2 2026, an estimated $190K.
  • Stonepine Capital Management first reported a position in Neumora Therapeutics in Q1 2026 and held it in 1 quarter.
  • Stonepine Capital Management's Neumora Therapeutics position peaked at $195K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.